Last week, Bristol-Myers Squibb (BMY) announced an additional $3B buyback program (see article here on avoiding stock) that signaled to investors to be cautious. While the amount sounded significant, the details suggested the buyback wouldn't amount to much more than 1.5% of the outstanding stock each year.
Now after the close on Friday, Bristol-Myers announced the agreement to purchase Amylin Pharmaceuticals (AMLN) along with AstraZeneca (AZN) for $5.3B. This deal surely suggests that the company won't buyback as much stock as expected at least in the near term.
The timing of the two announcements has to be in question. Why increase a buyback with the stock hitting a ten year high? Not to mention right before announcing a cash intensive acquisition that will not only strain any cash that could be used for a buyback, but also that is dilutive making the stock less attractive. Investors buying last week have to feel duped.
Read the full article at Seeking Alpha.
Disclosure: No position mentioned. Please review the disclaimer page for more details.